Arcturus Therapeutics Holdings Egenkapital 2024

Hvad gør Arcturus Therapeutics Holdings?

Arcturus Therapeutics is a biopharmaceutical company based in San Diego, California, founded in 2013. The company specializes in the development of RNA-based therapeutics and has developed a proprietary technology platform called "LUNAR" that enables safe and effective transport of RNA molecules into target cells. The technology, resulting from over a decade of research and development, allows for the development of drugs for a variety of diseases. Arcturus's business model focuses on forming partnerships with other pharmaceutical companies to accelerate the development of RNA-based therapeutics. The company collaborates with partners from various industries, ranging from large biotech companies to small startups, in order to promote the development of effective treatments. Arcturus also has its own pipeline of therapeutics in development. The company has formed partnerships with Janssen Pharmaceuticals, Takeda Pharmaceutical, Ultragenyx Pharmaceutical, and CureVac. Arcturus's pipeline includes a variety of therapeutics targeting different therapy areas, including oncology, critical care, and rare diseases. A key focus is on the treatment of liver diseases such as hemophilia B, alpha-1 antitrypsin deficiency, and factor VIII deficiency. Arcturus is also working on therapies for rare diseases like lysosomal storage disease and other diseases such as diabetes, kidney disease, and AIDS. One important product from Arcturus is the hepatitis B vaccine candidate, developed in partnership with Janssen Pharmaceuticals. The vaccine candidate utilizes Arcturus's LUNAR technology to generate an effective immune response against hepatitis B. Phase 2 studies of the vaccine have shown promising results, suggesting that the vaccine can play a significant role in combating hepatitis B. Another important product from Arcturus is ARO-AAT, developed for the treatment of alpha-1 antitrypsin deficiency. Deficiency of this protein can lead to liver and lung diseases, and currently there is no effective treatment method. ARO-AAT utilizes Arcturus's LUNAR technology to effectively transport RNA molecules to the affected cells. Clinical studies of ARO-AAT have been positively evaluated thus far. Arcturus also has plans to apply its RNA technology in the field of vaccine development, aiming to quickly and effectively respond to future pandemics and threats of infectious diseases. In summary, Arcturus Therapeutics is a biopharmaceutical company that has developed a proprietary RNA technology platform called LUNAR to develop safe and effective therapeutics for a variety of diseases. The company collaborates with a variety of partners to accelerate the development of RNA-based therapeutics. Arcturus has its own pipeline of therapeutics in development, including a hepatitis B vaccine candidate and ARO-AAT for the treatment of alpha-1 antitrypsin deficiency. The company also has plans to utilize its RNA technology for vaccine development to quickly and effectively respond to future infectious diseases. Arcturus Therapeutics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.